Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Aligos Therapeutics, Inc. (ALGS) had Weighted-Average Shares Outstanding (Diluted) of 9.88M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.17M |
|
$41.61M |
|
-- |
|
$0.17M |
|
$21.98M |
|
$-21.81M |
|
$1.96M |
|
$-19.85M |
|
$-19.85M |
|
$-19.88M |
|
$-19.88M |
|
$-19.88M |
|
$-19.88M |
|
$-21.81M |
|
$-23.38M |
|
9.88M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
9.88M |
$4.23 |
|
$4.23 |
|
| Balance Sheet Financials | |
$82.86M |
|
$1.87M |
|
$5.67M |
|
$88.53M |
|
$21.23M |
|
-- |
|
$13.76M |
|
$34.99M |
|
$53.55M |
|
$53.55M |
|
$53.55M |
|
6.18M |
|
| Cash Flow Statement Financials | |
$-82.50M |
|
$-37.83M |
|
$101.64M |
|
$37.11M |
|
$18.41M |
|
$-18.69M |
|
$5.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.90 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
100.00% |
|
-12907.68% |
|
-12907.68% |
|
-- |
|
-11746.14% |
|
24623.04% |
|
$-82.94M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-37.13% |
|
-37.13% |
|
-22.46% |
|
-37.13% |
|
$8.67 |
|
$-8.39 |
|
$-8.35 |
|